Evidence map›Paper›PMID 33284088›Full record

ReviewAmerican journal of physiology. Endocrinology and metabolism2021

Bilirubin as a metabolic hormone: the physiological relevance of low levels.

Justin F Creeden, Darren M Gordon, David E Stec, Terry D Hinds

Open access · greenAbstract readReview
In one paragraph

Review in American journal of physiology. Endocrinology and metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 142 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
142citing papers in PubMed, 2 pooled it
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

142 citing papers in PubMed, 2 syntheses or guidelines pooled it, 213 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Observational
  16. Review
  17. Article
  18. Article
  19. Neuroprotective role of bilirubin in Parkinson's disease.Frontiers in aging neuroscience · 2026
    Review
  20. Article

82 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Justin F CreedenDepartment of Neurosciences, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio.
Darren M GordonDepartment of Neurosciences, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio.
David E StecDepartment of Physiology & Biophysics, Cardiorenal and Metabolic Diseases Research Center, University of Mississippi Medical Center, Jackson, Mississippi.ORCID 0000-0001-8359-4008
Terry D HindsDepartment of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, Kentucky.
University of Toledo · USUniversity of Kentucky · USUniversity of Mississippi Medical Center · US

Funding

STRUCTURAL VASCULAR ADAPTATION OF THE MICROCIRCULATIONP01HL051971 · NHLBI · UNIVERSITY OF MISSISSIPPI MEDICAL CENTER · PI RECKELHOFF, JANE F · 1993 to 2018
$39.4M
Role of obesity in preeclamptic pregnancy.P20GM121334 · NIGMS · UNIVERSITY OF MISSISSIPPI MED CTR · PI Pier Paolo Claudio, Babbette LaMarca · 2017 to 2026
$26.4M
The role of leptin in autoimmune-associated hypertensionP20GM104357 · NIGMS · UNIVERSITY OF MISSISSIPPI MED CTR · PI HALL, JOHN E · 2013 to 2022
$23.4M
Novel Liver Signaling Pathways Controlling AdiposityR01DK121797 · NIDDK · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI HINDS, TERRY D · 2020 to 2024
$2.2M
Integrative Role of Bilirubin on ObesityR01DK121748 · NIDDK · UNIVERSITY OF MISSISSIPPI MED CTR · PI STEC, DAVID E · 2020 to 2023
$2.0M
Antioxidant-PPARalpha interaction and hypertensionK01HL125445 · NHLBI · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI HINDS, TERRY D · 2015 to 2019
$779k
HHS | NIH | National Heart, Lung, and Blood Institute (NHBLI) K01HL125445HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) R01DK126884NHLBI NIH HHS K01 HL125445NHLBI NIH HHS P01 HL051971NIDDK NIH HHS R01 DK121748NIDDK NIH HHS R01 DK121797NIGMS NIH HHS P20 GM104357NIGMS NIH HHS P20 GM121334
6 · The paper itself

Abstract

Recent research on bilirubin, a historically well-known waste product of heme catabolism, suggests an entirely new function as a metabolic hormone that drives gene transcription by nuclear receptors. Studies are now revealing that low plasma bilirubin levels, defined as "hypobilirubinemia," are a possible new pathology analogous to the other end of the spectrum of extreme hyperbilirubinemia seen in patients with jaundice and liver dysfunction. Hypobilirubinemia is most commonly seen in patients with metabolic dysfunction, which may lead to cardiovascular complications and possibly stroke. We address the clinical significance of low bilirubin levels. A better understanding of bilirubin's hormonal function may explain why hypobilirubinemia might be deleterious. We present mechanisms by which bilirubin may be protective at mildly elevated levels and research directions that could generate treatment possibilities for patients with hypobilirubinemia, such as targeting of pathways that regulate its production or turnover or the newly designed bilirubin nanoparticles. Our review here calls for a shift in the perspective of an old molecule that could benefit millions of patients with hypobilirubinemia.

Indexed as

Energy MetabolismAnimalsBilirubinGene Expression RegulationGilbert DiseaseHemeHormonesHumansHyperbilirubinemiaMetabolic Networks and PathwaysPPAR alphaBilirubinHemeHormonesPPAR alphabilirubin nanoparticlesheme oxygenaseHO-1hypobilirubinemiaPPARalpha

Identifiers

PMID33284088
PMCPMC8260361
OpenAlexW3111225026

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.